Literature DB >> 28603465

Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis.

Subhash Tummala, Tarun Singhal, Vinit V Oommen, Gloria Kim, Fariha Khalid, Brian C Healy, Rohit Bakshi.   

Abstract

Background: Monitoring patients with multiple sclerosis (MS) for “no evidence of disease activity” (NEDA) may help guide disease-modifying therapy (DMT) management decisions. Whereas surveillance brain magnetic resonance imaging (MRI) is common, the role of spinal cord monitoring for NEDA is unknown. Objective: To evaluate the role of brain and spinal cord 3T MRI in the 1-year evaluation of NEDA.
Methods: Of 61 study patients (3 clinically isolated syndrome, 56 relapsing-remitting, 2 secondary progressive), 56 (91.8%) were receiving DMT. The MRI included brain fluid-attenuated inversion recovery and cervical/thoracic T2-weighted fast spin echo images. On MRI, NEDA was defined as the absence of new or enlarging T2 lesions at 1 year.
Results: Thirty-nine patients (63.9%) achieved NEDA by brain MRI, only one of whom had spinal cord activity. This translates to a false-positive rate for NEDA based on the brain of 2.6% (95% CI, 0.1%–13.5%). Thirty-eight patients (62.3%) had NEDA by brain and spinal cord MRI. Fifty-five patients (90.2%) had NEDA by spinal cord MRI, 17 of whom had brain activity. Of the 22 patients (36.1%) with brain changes, 5 had spinal cord changes. No evidence of disease activity was sustained in 48.3% of patients at 1 year and was the same with the addition of spinal cord MRI. Patients with MRI activity in either the brain or the spinal cord only were more likely to have activity in the brain (P = .0001). Conclusions: Spinal cord MRI had a low diagnostic yield as an adjunct to brain MRI at 3T in monitoring patients with MS for NEDA over 1 year. Studies with larger data sets are needed to confirm these findings.

Entities:  

Year:  2017        PMID: 28603465      PMCID: PMC5460870          DOI: 10.7224/1537-2073.2016-068

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  46 in total

1.  Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?

Authors:  Carolyn J Bevan; Bruce A C Cree
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

2.  Spinal cord lesions in patients with multiple sclerosis: comparison of MR pulse sequences.

Authors:  K Hittmair; R Mallek; D Prayer; E G Schindler; H Kollegger
Journal:  AJNR Am J Neuroradiol       Date:  1996-09       Impact factor: 3.825

3.  Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

Authors:  James M Stankiewicz; Bonnie I Glanz; Brian C Healy; Ashish Arora; Mohit Neema; Ralph H B Benedict; Zachary D Guss; Shahamat Tauhid; Guy J Buckle; Maria K Houtchens; Samia J Khoury; Howard L Weiner; Charles R G Guttmann; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

4.  Spinal cord gray matter atrophy correlates with multiple sclerosis disability.

Authors:  Regina Schlaeger; Nico Papinutto; Valentina Panara; Carolyn Bevan; Iryna V Lobach; Monica Bucci; Eduardo Caverzasi; Jeffrey M Gelfand; Ari J Green; Kesshi M Jordan; William A Stern; H-Christian von Büdingen; Emmanuelle Waubant; Alyssa H Zhu; Douglas S Goodin; Bruce A C Cree; Stephen L Hauser; Roland G Henry
Journal:  Ann Neurol       Date:  2014-08-21       Impact factor: 10.422

5.  Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.

Authors:  Eva Havrdova; Steven Galetta; Michael Hutchinson; Dusan Stefoski; David Bates; Chris H Polman; Paul W O'Connor; Gavin Giovannoni; J Theodore Phillips; Fred D Lublin; Amy Pace; Richard Kim; Robert Hyde
Journal:  Lancet Neurol       Date:  2009-02-07       Impact factor: 44.182

6.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

7.  Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination.

Authors:  J C J Bot; F Barkhof; C H Polman; G J Lycklama à Nijeholt; V de Groot; E Bergers; H J Ader; J A Castelijns
Journal:  Neurology       Date:  2004-01-27       Impact factor: 9.910

8.  Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.

Authors:  Nancy L Sicotte; Rhonda R Voskuhl; Seth Bouvier; Rochelle Klutch; Mark S Cohen; John C Mazziotta
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

9.  Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Authors:  Douglas L Arnold; Peter A Calabresi; Bernd C Kieseier; Sarah I Sheikh; Aaron Deykin; Ying Zhu; Shifang Liu; Xiaojun You; Bjoern Sperling; Serena Hung
Journal:  BMC Neurol       Date:  2014-12-31       Impact factor: 2.474

10.  Age, gender and normalization covariates for spinal cord gray matter and total cross-sectional areas at cervical and thoracic levels: A 2D phase sensitive inversion recovery imaging study.

Authors:  Nico Papinutto; Regina Schlaeger; Valentina Panara; Alyssa H Zhu; Eduardo Caverzasi; William A Stern; Stephen L Hauser; Roland G Henry
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

View more
  2 in total

1.  The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI.

Authors:  Elena Di Sabatino; Lorenzo Gaetani; Silvia Sperandei; Andrea Fiacca; Giorgio Guercini; Lucilla Parnetti; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2021-11-24       Impact factor: 4.849

2.  Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis.

Authors:  Akram Dastagir; Brian C Healy; Alicia S Chua; Tanuja Chitnis; Howard L Weiner; Rohit Bakshi; Shahamat Tauhid
Journal:  eNeurologicalSci       Date:  2018-07-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.